The downregulation of Survivin expression/function has been shown to sensitize tumor cells to a variety of chemotherapeutic drugs, including cisplatin, paclitaxel, STX140, STX641, and trichostatin A [6,12,13,14,15,16,17,18], and inhibit EMT (epithelial–mesenchymal transition) [11,19]. Here, BIRC5 is linked to neoplasm.